-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
HC Wainwright Lowers ProQR Therapeutics (NASDAQ:PRQR) Price Target to $1.50
HC Wainwright Lowers ProQR Therapeutics (NASDAQ:PRQR) Price Target to $1.50
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) had its price objective dropped by equities research analysts at HC Wainwright from $2.00 to $1.50 in a research note issued on Monday, Benzinga reports. The firm presently has a "buy" rating on the biopharmaceutical company's stock. HC Wainwright's price objective indicates a potential upside of 71.62% from the company's previous close.
Several other research firms have also recently issued reports on PRQR. Chardan Capital cut ProQR Therapeutics from a "buy" rating to a "neutral" rating in a research report on Friday. Raymond James upgraded ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 price target for the company in a research report on Friday. StockNews.com upgraded ProQR Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, May 9th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of ProQR Therapeutics in a research report on Monday, May 9th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $4.93.
Get ProQR Therapeutics alerts:ProQR Therapeutics Price Performance
Shares of NASDAQ PRQR opened at $0.87 on Monday. The company has a debt-to-equity ratio of 0.43, a current ratio of 5.93 and a quick ratio of 5.93. The stock has a fifty day moving average price of $0.80 and a 200 day moving average price of $1.18. ProQR Therapeutics has a 1-year low of $0.53 and a 1-year high of $9.09. The company has a market cap of $62.31 million, a PE ratio of -0.86 and a beta of 0.80.
Institutional Trading of ProQR Therapeutics
Hedge funds have recently added to or reduced their stakes in the business. ProShare Advisors LLC acquired a new stake in ProQR Therapeutics in the 4th quarter worth about $80,000. Coastal Bridge Advisors LLC acquired a new position in shares of ProQR Therapeutics in the 4th quarter valued at about $85,000. Daiwa Securities Group Inc. lifted its stake in shares of ProQR Therapeutics by 22.1% in the 4th quarter. Daiwa Securities Group Inc. now owns 13,017 shares of the biopharmaceutical company's stock valued at $104,000 after purchasing an additional 2,352 shares in the last quarter. Corton Capital Inc. acquired a new position in shares of ProQR Therapeutics in the 4th quarter valued at about $280,000. Finally, Virtu Financial LLC acquired a new position in shares of ProQR Therapeutics in the 2nd quarter valued at about $48,000.ProQR Therapeutics Company Profile
(Get Rating)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
Read More
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- The Five Hottest Calls From The Q2 Earnings Season
- Here is a Simple 4 Stock Portfolio that Can Outperform the Market
- Is AMC Entertainment Pulling a Fast One on the APEs?
- Here's How the Inflation Reduction Act Energizes Power Stock
- 2 Important Retail Stock Battles to Watch
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) had its price objective dropped by equities research analysts at HC Wainwright from $2.00 to $1.50 in a research note issued on Monday, Benzinga reports. The firm presently has a "buy" rating on the biopharmaceutical company's stock. HC Wainwright's price objective indicates a potential upside of 71.62% from the company's previous close.
據Benzinga報道，在週一發佈的一份研究報告中，HC Wainwright的股票研究分析師將ProQR Treateutics(納斯達克：PRQR-GET評級)的目標價格從2.00美元下調至1.5美元。該公司目前對這家生物製藥公司的股票給予“買入”評級。HC Wainwright的目標價顯示，該公司較前一交易日收盤價有71.62%的潛在上漲空間。
Several other research firms have also recently issued reports on PRQR. Chardan Capital cut ProQR Therapeutics from a "buy" rating to a "neutral" rating in a research report on Friday. Raymond James upgraded ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 price target for the company in a research report on Friday. StockNews.com upgraded ProQR Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, May 9th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of ProQR Therapeutics in a research report on Monday, May 9th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $4.93.
其他幾家研究公司最近也發佈了關於PRQR的報告。在週五的一份研究報告中，Chardan Capital將ProQR治療公司的評級從“買入”下調至“中性”。Raymond James在週五的一份研究報告中將ProQR治療公司的評級從“市場表現”上調至“跑贏大盤”，併為該公司設定了2.00美元的目標價。在5月9日星期一的一份研究報告中，StockNews.com將ProQR治療公司的評級從“賣出”上調為“持有”。最後，坎託·菲茨傑拉德在5月9日星期一的一份研究報告中重申了對ProQR治療公司股票的“增持”評級。四名股票研究分析師對該股的評級為持有，五名分析師對該公司股票的評級為買入。根據MarketBeat的數據，該股的平均評級為“中等買入”，平均目標價為4.93美元。
ProQR Therapeutics Price Performance
ProQR治療藥物性價比
Shares of NASDAQ PRQR opened at $0.87 on Monday. The company has a debt-to-equity ratio of 0.43, a current ratio of 5.93 and a quick ratio of 5.93. The stock has a fifty day moving average price of $0.80 and a 200 day moving average price of $1.18. ProQR Therapeutics has a 1-year low of $0.53 and a 1-year high of $9.09. The company has a market cap of $62.31 million, a PE ratio of -0.86 and a beta of 0.80.
週一，納斯達克PRQR的股價開盤報0.87美元。該公司的債務權益比為0.43，流動比率為5.93，速動比率為5.93。該股的50日移動均價為0.80美元，200日移動均價為1.18美元。ProQR治療公司的一年低點為0.53美元，一年高位為9.09美元。該公司市值為6,231萬美元，市盈率為-0.86，貝塔係數為0.80。
Institutional Trading of ProQR Therapeutics
ProQR治療藥物的制度性交易
ProQR Therapeutics Company Profile
ProQR治療公司簡介
(Get Rating)
(獲取評級)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
ProQR Treateutics N.V.是一家生物製藥公司，致力於發現和開發基於RNA的治療遺傳疾病的療法。它主要開發正處於II/III期臨牀試驗的sepofarsen，用於治療Leber先天性黑髮10病的照明試驗；以及正在進行II/III期臨牀試驗的ultevursen，用於治療USH2A介導的視網膜色素變性和USHER綜合徵。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- The Five Hottest Calls From The Q2 Earnings Season
- Here is a Simple 4 Stock Portfolio that Can Outperform the Market
- Is AMC Entertainment Pulling a Fast One on the APEs?
- Here's How the Inflation Reduction Act Energizes Power Stock
- 2 Important Retail Stock Battles to Watch
- 免費獲取StockNews.com關於ProQR治療(PRQR)的研究報告
- 第二季度財報季最熱門的五個電話
- 以下是一個簡單的4只股票投資組合，它可以跑贏大盤
- AMC娛樂公司是在對猩猩採取快速行動嗎？
- 以下是《降低通脹法案》如何提振電力庫存
- 值得關注的兩場重要的零售股大戰
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受ProQR治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對ProQR治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧